LPL Financial LLC Buys 8,671 Shares of argenx SE (NASDAQ:ARGX)

LPL Financial LLC raised its stake in shares of argenx SE (NASDAQ:ARGX) by 113.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,317 shares of the company’s stock after purchasing an additional 8,671 shares during the quarter. LPL Financial LLC’s holdings in argenx were worth $10,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its position in shares of argenx by 28.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock valued at $1,875,000 after buying an additional 768 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in argenx by 4,344.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 40,842 shares of the company’s stock valued at $22,140,000 after acquiring an additional 39,923 shares during the last quarter. Captrust Financial Advisors purchased a new stake in argenx during the third quarter valued at about $243,000. Hilltop Holdings Inc. bought a new stake in argenx during the third quarter worth about $281,000. Finally, HighTower Advisors LLC boosted its holdings in shares of argenx by 11.7% in the 3rd quarter. HighTower Advisors LLC now owns 4,671 shares of the company’s stock worth $2,558,000 after purchasing an additional 489 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Performance

Shares of ARGX opened at $555.11 on Friday. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The firm’s 50-day simple moving average is $621.43 and its two-hundred day simple moving average is $602.61. The stock has a market cap of $33.73 billion, a PE ratio of -630.81 and a beta of 0.60.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Equities research analysts predict that argenx SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of recent research reports. Citigroup restated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. HC Wainwright lifted their target price on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Truist Financial restated a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, William Blair reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.